Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Theraphy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial
DSpace/Manakin Repository
Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Theraphy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial
| Title: | Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Theraphy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial |
| Author: |
Morrow, David Andrew; Wang, Yunmei; Croce, Kevin James; Sakuma, Masashi; Sabatine, Marc Steven; Gao, Huiyun; Pradhan, Aruna Das; Healy, Aileen M.; Buros, Jacki; McCabe, Carolyn; Libby, Peter; Cannon, Christopher Paul; Braunwald, Eugene; Simon, Daniel I.
Note: Order does not necessarily reflect citation order of authors. |
| Citation: | Morrow, David A., Yunmei Wang, Kevin Croce, Masashi Sakuma, Marc S. Sabatine, Huiyun Gao, Aruna D. Pradhan, et al. 2008. “Myeloid-Related Protein 8/14 and the Risk of Cardiovascular Death or Myocardial Infarction after an Acute Coronary Syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Theraphy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) Trial.” American Heart Journal 155 (1) (January): 49–55. doi:10.1016/j.ahj.2007.08.018. |
| Full Text & Related Files: |
Morrow_Myeloid- ... farction_AmHeartJ_2008.pdf (629.1Kb; PDF) 
|
| Abstract: | Background Using a transcriptional profiling approach, we recently identified myeloid-related protein 8/14 (MRP-8/14) to be expressed by platelets during acute myocardial infarction (MI). Elevated concentrations of MRP-8/14 are associated with a higher risk for future cardiovascular events in apparently healthy individuals but have not been assessed with respect to prognosis in patients with acute coronary syndrome.
Methods We performed a nested case-control study (n = 237 case-control pairs) among patients enrolled in the Pravastatin or Atorvastatin Evaluation and Infection Theraphy: Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial (mean follow-up 24 months) to investigate the risk of cardiovascular death or MI associated with MRP-8/14 measured at 30 days after an acute coronary syndrome. Results Patients with cardiovascular death or MI after 30 days (cases) had higher median [25th, 75th percentile] MRP-8/14 levels than patients who remained free of recurrent events (5.6 [2.8, 13.5] mg/L vs 4.0 [1.9, 10.1] mg/L, P = .020). The risk of a recurrent cardiovascular event increased with each increasing quartile of MRP-8/14 ( P-trend = 0.007) such that patients with the highest levels had a 2.0-fold increased odds (95% CI 1.1-3.6, P = .029) of a recurrent event after adjusting for standard risk indicators, randomized treatment, and C-reactive protein. Patients with elevated levels of MRP-8/14 and high-sensitivity C-reactive protein showed significantly increased risk of cardiovascular death or MI compared with patients with the lowest levels of both markers (adjusted odds ratio 2.1, 95% CI 1.2-3.8). Conclusions Myeloid-related protein 8/14 may be a useful biomarker of platelet and inflammatory disease activity in atherothrombosis and may serve as a novel target for therapeutic intervention. |
| Published Version: | doi:10.1016/j.ahj.2007.08.018 |
| Other Sources: | http://www.ncbi.nlm.nih.gov/pubmed/18082488 |
| Terms of Use: | This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA |
| Citable link to this page: | http://nrs.harvard.edu/urn-3:HUL.InstRepos:35140993 |
| Downloads of this work: |
This item appears in the following Collection(s)
-
HMS Scholarly Articles [19985]
Contact administrator regarding this item (to report mistakes or request changes)
